Drug interactions in oncology: how common are they?
Methods: We searched PubMed for eligible articles and on-line databases for abstracts of major oncology meetings.Results: Eight studies reported on the frequency of DDIs: six evaluated the frequency of potential DDIs, while two studies reported on real DDIs, i.e. interactions that had clinical conse...
| Autores: | , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2009 |
| País: | Brasil |
| Institución: | Universidade Federal de São Paulo (UNIFESP) |
| Repositorio: | Repositório Institucional da UNIFESP |
| Idioma: | inglés |
| OAI Identifier: | oai:repositorio.unifesp.br:11600/31959 |
| Acceso en línea: | http://dx.doi.org/10.1093/annonc/mdp369 http://repositorio.unifesp.br/handle/11600/31959 |
| Access Level: | acceso abierto |
| Palabra clave: | adverse effects drug interactions drug therapy neoplasms |
| Sumario: | Methods: We searched PubMed for eligible articles and on-line databases for abstracts of major oncology meetings.Results: Eight studies reported on the frequency of DDIs: six evaluated the frequency of potential DDIs, while two studies reported on real DDIs, i.e. interactions that had clinical consequences. Studies of potential DDIs found that approximately one-third of patients are exposed to dangerous drug doublets, with the most common ones involving warfarin and anticonvulsants. One study of real DDIs found that 2% of hospitalized cancer patients had a DDI as the cause of admission.Conclusions: Drug interactions comprise an important issue in oncology, with approximately one-third of ambulatory cancer patients being at risk of DDIs. Data are limited on the clinical consequences of drug interactions among cancer patients. |
|---|